SANG EUN LEE
Architects in Palo Alto, CA
License number
Massachusetts 50873
Issued Date
Jun 10, 2015
Expiration Date
Aug 31, 2017
Type
Architect
Address
Address
Palo Alto, CA 94304
Professional information
Antagonist Anti-Cd40 Monoclonal Antibodies And Methods For Their Use
US Patent:
2008005, Mar 6, 2008
Filed:
Nov 4, 2004
Appl. No.:
10/577390
Inventors:
Li Long - Hercules CA, US
Mohammad Luqman - Danville CA, US
Asha Yabannavar - Lafayette CA, US
Isabel Zaror - El Cerrito CA, US
Bao-Lu Chen - San Ramon CA, US
Xiaofeng Lu - Albany CA, US
Sang Hoon Lee - Palo Alto CA, US
Deborah Hurst - Piedmont CA, US
Mohammad Luqman - Danville CA, US
Asha Yabannavar - Lafayette CA, US
Isabel Zaror - El Cerrito CA, US
Bao-Lu Chen - San Ramon CA, US
Xiaofeng Lu - Albany CA, US
Sang Hoon Lee - Palo Alto CA, US
Deborah Hurst - Piedmont CA, US
Assignee:
Chiron Corporation - Eneryville CA
International Classification:
A61K 39/395, A61P 19/02, A61P 35/00, A61P 35/02, A61P 35/04, A61P 37/00, C07K 16/28, C12N 15/13, C12N 5/20
US Classification:
4241421, 4353431, 435375, 435377, 435 793, 53038815, 536 2353
Abstract:
Methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40 expressing cells, such as B cells.
Antagonist Anti-Cd40 Antibodies
US Patent:
8277810, Oct 2, 2012
Filed:
Oct 31, 2007
Appl. No.:
11/932472
Inventors:
Li Long - Hercules CA, US
Mohammad Luqman - Danville CA, US
Asha Yabannavar - Lafayette CA, US
Isabel Zaror - El Cerrito CA, US
Bao-Lu Chen - San Ramon CA, US
Xiaofeng Lu - Albany CA, US
Sang Hoon Lee - Palo Alto CA, US
Deborah Hurst - Piedmont CA, US
Mohammad Luqman - Danville CA, US
Asha Yabannavar - Lafayette CA, US
Isabel Zaror - El Cerrito CA, US
Bao-Lu Chen - San Ramon CA, US
Xiaofeng Lu - Albany CA, US
Sang Hoon Lee - Palo Alto CA, US
Deborah Hurst - Piedmont CA, US
Assignee:
Novartis Vaccines & Diagnostics, Inc. - Emeryville CA
International Classification:
A61K 39/395, C07K 16/28
US Classification:
4241531, 4241301, 4241331, 4241411, 4241431, 4241441, 4241521, 4241731, 5303871, 5303873, 5303881, 5303882, 53038822, 5303887, 53038873
Abstract:
Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.
Antagonist Anti-Cd40 Monoclonal Antibodies And Methods For Their Use
US Patent:
8637032, Jan 28, 2014
Filed:
Sep 12, 2012
Appl. No.:
13/612070
Inventors:
Li Long - Hercules CA, US
Asha Yabannavar - Lafayette CA, US
Isabel Zaror - El Cerrito CA, US
Sang Hoon Lee - Palo Alto CA, US
Deborah Hurst - Piedmont CA, US
Asha Yabannavar - Lafayette CA, US
Isabel Zaror - El Cerrito CA, US
Sang Hoon Lee - Palo Alto CA, US
Deborah Hurst - Piedmont CA, US
Assignee:
Novartis Vaccines and Diagnostics, Inc. - Emeryville CA
International Classification:
A61K 39/395, C07K 16/28
US Classification:
4241531, 4241301, 4241331, 4241411, 4241431, 4241441, 4241521, 4241731, 5303871, 5303873, 5303881, 5303882, 53038822, 5303887, 53038873
Abstract:
Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.